10-Q: Waters Q3 Sales Up 8% Amidst Major BD Merger Costs

Waters Corporation reported an 8% increase in Q3 net sales to $799.9 million, driven by strong demand for Waters Division products, though operating income declined due to significant merger-related and ERP implementation costs.

Summary

• Net sales increased by 8% to $799.9 million for the three months ended September 27, 2025, and by 7% to $2.23 billion for the nine months ended September 27, 2025, compared to the prior year periods.
• Operating income decreased by 9% to $192.1 million for the three months, primarily due to $31 million in merger transaction and integration costs and $6 million in ERP system implementation expenses.
• Net income decreased by 8% to $148.9 million for the three months, and diluted EPS decreased by 8% to $2.50.
• For the nine months, net income increased by 3% to $417.4 million, and diluted EPS increased by 2% to $7.00.
• The company entered into definitive agreements on July 13, 2025, to acquire BD's Biosciences and Diagnostic Solutions business in a $17.5 billion Reverse Morris Trust transaction, expected to close in Q1 2026.
• Acquired Halo Labs for $35 million on May 20, 2025, enhancing biopharmaceutical formulation and quality control tools.
• Initiated a new worldwide ERP system implementation, with an anticipated total spend of $130 million over three years.

Sentiment

Score: 6

Explanation: While sales growth is positive and strategic acquisitions are underway, the significant costs associated with the BD merger and ERP implementation, coupled with a decline in Q3 operating income and EPS, temper the overall sentiment. The long-term strategic benefits are promising but carry substantial execution and financial risks.

Positives

• Strong net sales growth of 8% for Q3 2025 and 7% for the first nine months of 2025, driven by demand for Waters Division products and services.
• Waters instrument system sales increased by 6% in Q3 and 8% in 9M, led by LC-MS systems.
• Waters chemistry consumables sales grew significantly by 14% in Q3 and 11% in 9M, attributed to demand from pharmaceutical customers.
• Sales to pharmaceutical customers increased by 12% in Q3 and 9% in 9M across most regions.
• Geographic sales growth was broad-based, with China sales up 13% (Q3) and 12% (9M), and Europe sales up 13% (Q3) and 9% (9M).
• Net income for the nine months ended September 27, 2025, increased by 3% to $417.4 million.
• Diluted EPS for the nine months ended September 27, 2025, increased by 2% to $7.00.
• Net cash provided by operating activities was $488 million for the first nine months of 2025.
• The weighted-average interest rate on debt decreased to 3.39% at September 27, 2025, from 3.72% at December 31, 2024.
• Interest rate cross-currency swap agreements lowered net interest expense by approximately $8 million in the first nine months of 2025 and are expected to lower it by $10 million in 2025.
• No litigation provisions were recorded in the first nine months of 2025, compared to $12 million in the prior year.
• Accumulated other comprehensive loss improved from $(155.3) million at December 31, 2024, to $(111.2) million at September 27, 2025.

Negatives

• Operating income decreased by 9% in Q3 2025 and by less than 1% in 9M 2025, primarily due to significant transaction and integration costs related to the BD merger and ERP implementation expenses.
• Net income decreased by 8% in Q3 2025 to $148.9 million.
• Diluted EPS decreased by 8% in Q3 2025 to $2.50.
• Selling and administrative expenses increased significantly by 27% in Q3 and 14% in 9M, partly due to merger-related costs and ERP implementation.
• Interest expense, net, increased by $5 million in Q3 2025, primarily due to $14 million in financing costs paid on behalf of SpinCo related to the merger.
• Net cash provided by operating activities decreased to $488 million in 9M 2025 from $522 million in 9M 2024, impacted by higher tax payments and merger/ERP costs.
• Net cash used in investing activities increased to $110 million in 9M 2025 from $92 million in 9M 2024, partly due to the Halo Labs acquisition.
• TA segment sales decreased by 1% for the first nine months of 2025, with U.S. industrial sales declining by 9% in Q3 due to lower demand for TA instrument systems.
• Increase in inventory by $66 million in 9M 2025, attributed to higher tariffs and increased safety stock levels.

Risks

• Risks related to the BD Merger, including failure to satisfy or waive closing conditions, delays in obtaining regulatory approvals (potentially exacerbated by U.S. government shutdown), or failure to realize anticipated benefits and synergies.
• Risk of termination of the Merger Agreement, which could require Waters to pay a $733 million termination fee to BD.
• Uncertainty regarding the tax-free nature of the Spin-Off and the number of shares of Waters Common Stock to be issued, potentially diluting existing shareholders.
• Increased indebtedness following the Merger, which may reduce financial flexibility, lower credit ratings, increase borrowing costs, or require reductions in investments.
• Global economic and financial market conditions, including fluctuations in foreign currency exchange rates, inflation, and interest rates.
• Impacts and costs of war, particularly ongoing conflicts in Russia-Ukraine and the Middle East, and potential geopolitical instability.
• Economic conditions in China, trade tensions and tariffs between the U.S. and China, increased competition, and government procurement restrictions in China.
• Ability to access capital, maintain liquidity, and service debt in volatile market conditions.
• Changes in timing and demand for products among customers and various market sectors due to expenditure fluctuations or funding availability.
• Introduction of competing products by other companies and loss of market share, as well as pressures on prices from competitors and/or customers.
• Regulatory, economic, and competitive obstacles to new product introductions and inability to grow organically through innovation.
• Rapidly changing technology and product obsolescence.
• Risks related to the development, deployment, and use of artificial intelligence (AI) and a failure to timely and effectively use AI and embed it into new product offerings and services that negatively impacts competitiveness.
• Risks associated with previous or future acquisitions, strategic investments, joint ventures, and divestitures, including risks associated with achieving the anticipated financial results and operational synergies, contingent purchase price payments, and expansion into new or developing markets.
• Risks associated with unexpected disruptions in operations, including risks associated with the transition to a new ERP system.
• Risks related to any public health crisis or pandemic, climate change, severe weather and geological conditions or events or other events beyond control.
• Failure to adequately protect intellectual property, infringement of intellectual property rights of third parties, and inability to obtain licenses on commercially reasonable terms.
• Ability to acquire adequate sources of supply and reliance on outside contractors for certain components and modules, as well as disruptions to the supply chain.
• Risks associated with third-party sales intermediaries and resellers.
• The impact and costs of changes in statutory or contractual tax rates in jurisdictions in which the company operates as well as shifts in taxable income among jurisdictions with different effective tax rates, the outcome of ongoing and future tax examinations, and changes in legislation affecting the effective tax rate.
• Ability to attract and retain qualified employees and management personnel.
• Risks associated with cybersecurity and information technology infrastructure, including attempts by third parties, both private and state-sponsored, to defeat information security measures and gain unauthorized access to sensitive and proprietary company products, services, systems, or data.
• Risks associated with compliance with data privacy and information security laws and regulations regarding the collection, transmission, storage, and use of personally identifying information.
• Increased regulatory burdens as the business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others, and in connection with government contracts.
• Regulatory, environmental, and logistical obstacles affecting the distribution of products, completion of purchase order documentation, and the ability of customers to obtain letters of credit or other financing alternatives.
• Risks associated with litigation and other legal and regulatory proceedings.
• The impact and costs incurred from changes in accounting principles and practices.

Future Outlook

The company anticipates the $17.5 billion acquisition of BD's Biosciences and Diagnostic Solutions business to close around the end of the first quarter of calendar year 2026, subject to regulatory and shareholder approvals. It expects to incur approximately $140 million in total transaction-related expenses and financing fees if the merger closes. The company also plans to spend approximately $130 million on a new worldwide ERP system implementation over the next three years and expects interest rate swap agreements to lower net interest expense by approximately $10 million in 2025. The U.S. Supreme Court is anticipated to hear oral arguments regarding tariffs in November 2025, which could impact future financial results.

Management Comments

• "It is management's opinion that the accompanying interim consolidated financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods."
• "While the Company believes that these actions and policies will mitigate a substantial portion of the impact of the tariffs, the Company cannot provide any assurances that the tariffs or any resulting impediments to trade will not have a material effect on the Company's consolidated statement of operations and statement of cash flows."
• "The Company believes it has meritorious arguments in its current litigation matters and believes any outcome, either individually or in the aggregate, will not be material to the Company's financial position, results of operations or cash flows."
• "The Company has not paid any dividends and has no plans, at this time, to pay any dividends in the future."

Industry Context

The company operates in the analytical instrument industry, serving life, materials, and food sciences. The acquisition of BD Biosciences & Diagnostic Solutions is a significant strategic move to create a leading global life sciences and diagnostics company, enhancing scale and expanding end-market exposure. The industry faces risks from global economic conditions, foreign currency fluctuations, technological innovations from competitors, and regulatory changes, including tariffs and government funding shifts. The company's strong performance in Waters Division products, particularly LC-MS and chemistry consumables for pharmaceutical customers, indicates robust demand in the biopharmaceutical sector. However, the TA segment's slight decline, especially in U.S. industrial sales, suggests some market softness in specific areas.

Legal Proceedings

• No material changes in legal proceedings during the nine months ended September 27, 2025.
• No litigation provisions were recorded in the first nine months of 2025, compared to $12 million in patent litigation settlement provisions and related costs in the prior year.

Stakeholder Impact

• Shareholders: Potential dilution from the BD merger (BD shareholders to own ~39.2% of combined company). Potential for a Waters Special Dividend. Stock price volatility expected due to merger pendency. Long-term potential for enhanced scale and market exposure from the BD merger.
• Employees: Potential for organizational changes and integration challenges due to the BD merger. Merit increases were a factor in increased selling and administrative, and R&D expenses.
• Customers: Continued strong demand for Waters Division products and services. Acquisition of Halo Labs expands product offerings in biopharmaceutical formulation and quality control.
• Creditors: Increased indebtedness expected post-merger, potentially impacting credit ratings and borrowing costs. The company is in compliance with all debt covenants.
• Suppliers: Potential supply chain disruptions due to tariffs and increased safety stock levels.

Next Steps

• Complete the acquisition of BD's Biosciences and Diagnostic Solutions business, expected around the end of Q1 2026, subject to regulatory and shareholder approvals.
• Replace the $1.8 billion bridge facility with permanent financing, potentially a delayed draw term loan facility.
• Continue implementation of the new worldwide ERP system, with anticipated spending of $130 million over the next three years.
• Monitor the impact of the U.S. Supreme Court's decision on tariffs, with oral arguments anticipated in November 2025.
• Monitor the adoption of Pillar Two global minimum tax rules in additional jurisdictions.
• Monitor the impact of the One Big Beautiful Tax Bill Act (OBBB) in future periods.
• Potentially declare and pay a Waters Special Dividend to shareholders, depending on the merger's exchange ratio adjustments.

Key Dates

Recommendation

The company demonstrates solid underlying sales growth in its core Waters segment, particularly in pharmaceutical markets, and is undertaking a transformative acquisition of BD Biosciences & Diagnostic Solutions. This merger, while strategically significant, introduces substantial integration risks, increased debt, and near-term financial headwinds from transaction costs and ERP implementation, which have already impacted Q3 operating income and EPS. The long-term benefits are promising, but the execution risks and the current financial strain warrant a cautious "hold" stance until there is clearer visibility on merger integration, debt management, and the realization of anticipated synergies. The stock price is likely to remain volatile given the scale of the transaction and associated uncertainties.

Keywords

Waters Corporation, SEC 10-Q, Quarterly Report, Financial Results, BD Biosciences Acquisition, Halo Labs Acquisition, Life Sciences, Analytical Instruments, Mass Spectrometry, Chromatography, Thermal Analysis, ERP System, Debt Management, Share Repurchase, Pharmaceutical Market, China Sales, Foreign Currency Risk, Supply Chain, Regulatory Approvals, Merger & Acquisition, Biopharmaceutical, Laboratory Equipment